Agalsidase alfa is indicated for:
Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, the medical literature mentions below treatments (click for details):
Irrespective of gender only Adults (18 - 65 years old)
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Agalsidase alfa is contraindicated in the following cases:
Agalsidase alfa should not be co-administered with amiodarone since this substance has the potential to inhibit intra-cellular α-galactosidase activity.
Agalsidase alfa should not be co-administered with chloroquine since this substance has the potential to inhibit intra-cellular α-galactosidase activity.
Agalsidase alfa should not be co-administered with gentamicin since this substance has the potential to inhibit intra-cellular α-galactosidase activity.